BioCorRx Recovery Program Used in Lieu of Conviction in Ohio

ANAHEIM, CA, Dec. 22, 2017 --

BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that that the Company’s BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, was featured on CBC affiliate WBNS-10TV news in Ohio. The program features an individual suffering from opioid use disorder who has turned his life around since starting the BioCorRx Recovery Program. Participation in the Company’s program was accepted in lieu of conviction by a Richland County judge in Ohio. 

A link to the news story is available at: https://www.10tv.com/article/hi-tech-treatment-now-possible-opiate-addiction. After the segment aired, an update of the cost for treatment was posted in the written article associated with the video. The cost mentioned is the national average for the entire outpatient program that varies by each independent location and also typically includes medical follow-ups, cognitive behavioral therapy (CBT) with a licensed therapist for approximately 3 months and an overlapping peer recovery support and patient outcome tracking for one full year. In some cases, it may even include outpatient detox. 

Brady Granier, CEO, President, and Director of BioCorRx, commented, “It’s great to see our program featured in Ohio, one of the states most devastated by the opioid epidemic. More importantly, it’s emotionally rewarding to see people get on their journey to recovery with our program. We are also honored that our program was approved to be utilized as treatment in lieu of conviction. We hope to see more of this in the future as it can help people get well and on the road to recovery, while also reducing the financial burden of incarceration on society.”

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com. 

Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc.
[email protected]
714-462-4880

Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
[email protected]